Literature DB >> 20226165

Celastrol: Molecular targets of Thunder God Vine.

Antero Salminen1, Marko Lehtonen, Tuomas Paimela, Kai Kaarniranta.   

Abstract

Celastrol, a quinone methide triterpene, is a pharmacologically active compound present in Thunder God Vine root extracts used as a remedy of inflammatory and autoimmune diseases, e.g. rheumatoid arthritis. Celastrol is one of the most promising medicinal molecules isolated from the plant extracts of traditional medicines. Molecular studies have identified several molecular targets which are mostly centered on the inhibition of IKK-NF-kappaB signaling. Celastrol (i) inhibits directly the IKKalpha and beta kinases, (ii) inactivates the Cdc37 and p23 proteins which are co-chaperones of HSP90, (iii) inhibits the function of proteasomes, and (iv) activates the HSF1 and subsequently triggers the heat shock response. It seems that the quinone methide structure present in celastrol can react with the thiol groups of cysteine residues, forming covalent protein adducts. In laboratory experiments, celastrol has proved to be a potent inhibitor of inflammatory responses and cancer formation as well as alleviating diseases of proteostasis deficiency. Celastrol needs still to pass several hurdles, e.g. ADMET assays, before it can enter the armoury of western drugs. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226165     DOI: 10.1016/j.bbrc.2010.03.050

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  101 in total

Review 1.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 2.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

3.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

4.  Celastrol may have an anti-atherosclerosis effect in a rabbit experimental carotid atherosclerosis model.

Authors:  Feng Zhu; Cai Li; Xiao-Ping Jin; Shou-Xiang Weng; Li-Long Fan; Zhou Zheng; Wei-Ling Li; Feng Wang; Wan-Fen Wang; Xiao-Fei Hu; Chen-Ling Lv; Peng Liu
Journal:  Int J Clin Exp Med       Date:  2014-07-15

5.  Celastrol-loaded PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis.

Authors:  Sean D Allen; Yu-Gang Liu; Taehyeung Kim; Sharan Bobbala; Sijia Yi; Xiaohan Zhang; Jaehyuk Choi; Evan A Scott
Journal:  Biomater Sci       Date:  2019-01-29       Impact factor: 6.843

Review 6.  Natural compounds as anticancer agents: Experimental evidence.

Authors:  Jiao Wang; Yang-Fu Jiang
Journal:  World J Exp Med       Date:  2012-06-20

Review 7.  Cdc37 as a co-chaperone to Hsp90.

Authors:  Stuart K Calderwood
Journal:  Subcell Biochem       Date:  2015

Review 8.  Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?

Authors:  Subhankar Paul; Sailendra Mahanta
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

9.  Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease.

Authors:  Bong-Suk Choi; Hyool Kim; Hyo Jeong Lee; Kumar Sapkota; Se Eun Park; Seung Kim; Sung-Jun Kim
Journal:  Neurochem Res       Date:  2013-11-09       Impact factor: 3.996

10.  Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Zheng Hu; Fu-Qun Wu; Wei Li; Jinsong Liu; Guang-Biao Zhou
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.